Anetumab ravtansine, an anti-mesothelin antibody-drug conjugate, is undergoing Phase I trials to recruit patients with advanced-stage CCA with abnormal expression of mesothelin [12]. The gene discussed is MSLN; the disease is cholangiocarcinoma.